Woodle E Steve, Alloway Rita, Rike Adele, Roy-Chaudhury Prabir, Tevar Amit, Susskind Brian, Everly Jason, Mogilishetty Gautham, Brailey Paul, Govil Amit, Rudich Steve, First M Roy, Alexander J Wesley, Munda Rino, Cardi Michael, Arend Lois
University of Cincinnati, the Christ Hospital, Cincinnati, Ohio, USA.
Clin Transpl. 2007:51-60.
Elimination of corticosteroid-related morbidity has been a goal of transplant clinicians from the earliest days of renal transplantation more than 50 years ago. Over the past decade, this goal has begun to be realized. Herein, we describe our efforts to eliminate corticosteroid therapy from maintenance immunosuppression-efforts that have spanned 15 years and have included design and conduct of five multicenter trials and over ten single center trials with over 650 patients at the University of Cincinnati. These efforts have led to a near complete elimination of corticosteroid-related morbidity, and, importantly, a more precise definition of the risk/benefit assessments of corticosteroid withdrawal in individual patient populations, which has allowed individualization and tailoring of corticosteroid-free immunosuppression.
消除与皮质类固醇相关的发病情况一直是自50多年前肾移植最早时期以来移植临床医生的目标。在过去十年中，这一目标已开始实现。在此，我们描述了我们在维持免疫抑制中消除皮质类固醇疗法的努力——这些努力跨越了15年，包括设计和开展了五项多中心试验以及十多项单中心试验，涉及辛辛那提大学的650多名患者。这些努力已使与皮质类固醇相关的发病情况几乎完全消除，而且重要的是，对个体患者群体中停用皮质类固醇的风险/获益评估有了更精确的定义，这使得无皮质类固醇免疫抑制能够个体化并量身定制。
